Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Spotty Progress on Single-Use Standards
Vendors Work to Standardize Protocols but Resist End Users’ Calls for Interoperability
- Intellectual property issues and lifecycle-level business decisions seriously limit inter-vendor interoperability for single-use bioprocessing equipment. Nevertheless, standards are evolving through the collaboration between vendor and end-user working groups. Within a few years we can expect consensus on issues related to materials of construction for films, tubing, and connectors, and ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.